2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
Annals of the Rheumatic Diseases · 2023-06 · 82 (6) · 742-753
DOI: 10.1136/ard-2022-223335 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of the Rheumatic Diseases, 2023-06. Verfasst von George E Fragoulis und 23 weiteren Autor:innen. Beteiligte Einrichtung: Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, …. Hauptthemen laut MEDLINE: Antirheumatic Agents, Opportunistic Infections, Rheumatic Diseases. Die Arbeit wurde bisher 246-mal zitiert (Crossref) und nennt 209 Literaturangaben. Gefördert von: KLH is also supported by the NIHR Manchester Biomedical Research Centre., EULAR Quality of Care Committee.
Abstract (Originalsprache)
OBJECTIVES: To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). METHODS: An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member. RESULTS: Four overarching principles (OAP) and eight recommendations were developed. The OAPs highlight the need for infections to be discussed with patients and with other medical specialties, in accordance with national regulations. In addition to biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for which screening for latent tuberculosis (TB) should be performed, screening could be considered also before conventional synthetic DMARDs, glucocorticoids and immunosuppressants. Interferon gamma release assay should be preferred over tuberculin skin test, where available. Hepatitis B (HBV) antiviral treatment should be guided by HBV status defined prior to starting antirheumatic drugs. All patients positive for hepatitis-C-RNA should be referred for antiviral treatment. Also, patients who are non-immune to varicella zoster virus should be informed about the availability of postexposure prophylaxis should they have contact with this pathogen. Prophylaxis against Pneumocystis jirovecii seems to be beneficial in patients treated with daily doses >15-30 mg of prednisolone or equivalent for >2-4 weeks. CONCLUSIONS: These recommendations provide guidance on the screening and prevention of chronic and opportunistic infections. Their adoption in clinical practice is recommended to standardise and optimise care to reduce the burden of opportunistic infections in people living with AIIRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
- Centre for Rheumatic Diseases, King's College London, London, UK.
- Rheumatology Department, King's College London, London, UK.
- Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
- Rheumatology Department, Countess of Chester Hospital NHS Foundation Trust, Chester, UK.
ORCID-Profile: George E Fragoulis, Elena Nikiphorou, Mrinalini Dey, Delphine Sophie Courvoisier, Laurent Arnaud, Kim Lauper, Mariana Luís, György Nagy, Marco Sebastiani, Anja Strangfeld, Annette de Thurah, James Galloway, Kimme L Hyrich
Förderung
- KLH is also supported by the NIHR Manchester Biomedical Research Centre.
- EULAR Quality of Care Committee
Zitieren
APA
Fragoulis, G. E., Nikiphorou, E., Dey, M., Zhao, S. S., Courvoisier, D. S., Arnaud, L., Atzeni, F., Behrens, G. M., Bijlsma, J. W., Böhm, P., Constantinou, C. A., Garcia-Diaz, S., Kapetanovic, M. C., Lauper, K., Luís, M., Morel, J., Nagy, G., Polverino, E., van Rompay, J., …, & Hyrich, K. L. (2023). 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, 82(6), 742-753. https://doi.org/10.1136/ard-2022-223335
Vancouver
Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases. 2023;82(6):742-753. doi:10.1136/ard-2022-223335
BibTeX
@article{Fragoulis2023,
author = {Fragoulis, George E and Nikiphorou, Elena and Dey, Mrinalini and Zhao, Sizheng Steven and Courvoisier, Delphine Sophie and Arnaud, Laurent and Atzeni, Fabiola and Behrens, Georg Mn and Bijlsma, Johannes Wj and Böhm, Peter and Constantinou, Costas A and Garcia-Diaz, Silvia and Kapetanovic, Meliha Crnkic and Lauper, Kim and Luís, Mariana and Morel, Jacques and Nagy, György and Polverino, Eva and van Rompay, Jef and Sebastiani, Marco and Strangfeld, Anja and de Thurah, Annette and Galloway, James and Hyrich, Kimme L},
title = {2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases},
journal = {Annals of the Rheumatic Diseases},
year = {2023},
volume = {82},
number = {6},
pages = {742--753},
doi = {10.1136/ard-2022-223335}
}
EUVIMED